Compare Nomura Holdings Inc (NMR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Novartis AG — how do they compare? Nomura Holdings Inc trades at $9.4 (market cap $27.46B), while Novartis AG trades at $149.81 (market cap $290.25B). The key difference: Novartis AG is far larger — about 10.6× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| NMR | NVS | |
|---|---|---|
Market Cap | $27.46B | $290.25B |
Sector | Financials | Health |
52-Week High | $10.04 | $168.62 |
52-Week Low | $6.39 | $113.50 |
Dividend Yield | 3.45% | 3.17% |
Enterprise Value | — | $330.27B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
